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Abstract
Dioleoylphosphatidylethanolamine (DOPE)-containing liposomes that demonstrated pH-dependent release of their
contents were stabilized in the bilayer form through the addition of a cleavable lipid derivative of polyethylene glycol (PEG)
in which the PEG was attached to a lipid anchor via a disulfide linkage (mPEG-S-S-DSPE). Liposomes stabilized with either
a non-cleavable PEG (mPEG-DSPE) or mPEG-S-S-DSPE retained an encapsulated dye at pH 5.5, but treatment at pH 5.5
of liposomes stabilized with mPEG-S-S-DSPE with either dithiothreitol or cell-free extracts caused contents release due to
cleavage of the PEG chains and concomitant destabilization of the DOPE liposomes. While formulations loaded with
doxorubicin (DXR) were stable in culture media, DXR was rapidly released in human plasma. pH-Sensitive liposomes,
targeted to the CD19 epitope on B-lymphoma cells, showed enhanced DXR delivery into the nuclei of the target cells and
increased cytotoxicity compared to non-pH-sensitive liposomes. Pharmacokinetic studies suggested that mPEG-S-S-DSPE
was rapidly cleaved in circulation. In a murine model of B-cell lymphoma, the therapeutic efficacy of an anti-CD19-targeted
pH-sensitive formulation was superior to that of a stable long-circulating formulation of targeted liposomes despite the more
rapid drug release and clearance of the pH-sensitive formulation. These results suggest that targeted pH-sensitive
formulations of drugs may be able to increase the therapeutic efficacy of entrapped drugs. ß 2001 Elsevier Science B.V. All
rights reserved.
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Abbreviations: CFE, cell-free extract; CHEMS, cholesteryl hemisuccinate; CHOL, cholesterol; [3H]CHE, cholesteryl-(1,2-[3H](N)]-
hexadecyl ether; DOPE, dioleoylphosphatidylethanolamine; DPX, p-xylene-bis-pyridinium bromide; DSPE, distearoylphosphatidyletha-
nolamine; DTT, dithiothreitol ; DXR, doxorubicin; FBS, fetal bovine serum; HEPES, 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic
acid; HPTS, trisodium 8-hydroxypyrenetrisulfonate; HSPC, hydrogenated soy phosphatidylcholine; IC50, drug concentration at which
cell growth is inhibited by 50%; mAb, monoclonal antibody; mPEG-DSPE, methoxypoly(ethylene glycol) (Mr 2000) covalently coupled
to DSPE; Mal-PEG-DSPE, maleimide-terminated polyethylene glycol (Mr 2000) covalently coupled to DSPE; mPEG-S-S-DSPE, N-[2-g-
methoxypoly(ethylene glycol)-K-aminocarbonylethyl-dithiopropionyl]-DSPE; MES, N-morpholinoethanesulfonic acid; MPS, mononu-
clear phagocyte system; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PL, phospholipid; SL, sterically stabilized
(Stealth) liposomes composed of HSPC/CHOL/mPEG-DSPE; DXR-SL, SL loaded with doxorubicin; SIL[anti-CD19], sterically-stabi-
lized (Stealth) immunoliposomes composed of HSPC/CHOL/mPEG-DSPE/Mal-PEG-DSPE covalently coupled to mAb anti-CD19;
DXR-SIL, SIL loaded with doxorubicin; TI, tyraminylinulin
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1. Introduction
Long-circulating liposomal doxorubicin (DXR),
Caelyx/Doxil, is currently approved for clinical use
in the treatment of refractory Kaposi’s sarcoma and
ovarian cancer [1^3]. However, the passive targeting
approach that has made liposomal drugs successful
in the treatment of solid tumors will be less success-
ful when applied to haematological malignancies. To
increase the uptake of liposomal drugs by malignant
B cells, a ligand-mediated targeting approach has
been employed [4]. Many investigators have eval-
uated long-circulating targeted liposomes (sterically-
stabilized immunoliposomes, SIL), which have anti-
bodies, their fragments or other ligands attached to
the PEG termini, for their ability to increase the
selective delivery of liposomal contents to target tis-
sues and cells in vivo and in vitro [4^14]. We have
reported that anti-CD19-targeted sterically-stabilized
liposomes (SIL[anti-CD19]) bound selectively to
CD19 human B-lymphoma cells, triggering endocy-
tosis of the liposomes [15]. The encapsulated DXR
accumulated in the endosomes of the target cells and
was released from the endosomes into the cytoplasm
only very slowly. This has led us to hypothesize that
a more rapid rate of release of the drug from the
endosomes would lead to more rapid delivery of
the drug to its intracellular site of action, resulting
in improved therapeutic e⁄cacy for the targeted lipo-
somal drugs.
The lipid dioleoylphosphatidylethanolamine
(DOPE) adopts a nonbilayer (hexagonal, HII) struc-
ture in an aqueous medium at neutral pH [16^18]
but, when combined with stabilizing components
such as cholesteryl hemisuccinate (CHEMS) [16],
the lipids can assemble into a bilayer. These lipo-
somes are postulated to destabilize in the acidic en-
vironment of the endosomes, rapidly releasing their
contents [16,19,20]. Current formulations of pH-sen-
sitive liposomes are unstable in blood and are rapidly
cleared from the circulation by the mononuclear
phagocyte system (MPS) [21,22]. One way to increase
their circulation half-life is to include lipid deriva-
tives of PEG in the liposome formulations, but this
leads to a decrease in the pH-dependant release of
dye from these liposomes [23,24]. A PEG-lipid deriv-
ative with a disul¢de linkage (mPEG-S-S-DSPE) has
been synthesized by Zalipsky [25]. Thiolytic cleavage
of the grafted PEG from the surface of pH-sensitive
formulations restored pH sensitivity, leading to re-
lease of the liposomal contents [25,26]. This linker
is hypothesized to resist cleavage in the circulation.
Targeting ligands bound to these liposomes may al-
low the liposomes to circulate long enough to bind
to, and be internalized by, the target cells. Subse-
quently, cleavage of the disul¢de linkage by lysoso-
mal enzymes within the target cells should lead to a
restoration of the pH sensitivity and allow rapid con-
tent release and increased cytotoxicity.
Here we report the development of anti-CD19-tar-
geted, DXR-loaded, pH-sensitive liposomes stabi-
lized with PEG-lipid derivatives, which can be ex-
pected to selectively deliver their contents to target
cells with rapid intracellular drug release. Compari-
sons are made of liposomes containing either cleav-
able PEG (mPEG-S-S-DSPE) or non-cleavable PEG
(mPEG-DSPE) as stabilizing components. The lipo-
somes are characterized in vitro as to drug release
properties and cytotoxicity against a CD19 human
B-lymphoma cell line (Namalwa). In addition, we
test the therapeutic e⁄cacy of the formulations in
vivo in SCID mice implanted with the Namalwa
cell line.
2. Materials and methods
2.1. Materials
Hydrogenated soy phosphatidylcholine (HSPC),
mPEG2000-distearoylphosphatidyl-ethanolamine
(mPEG2000-DSPE, also abbreviated mPEG-DSPE)
and doxorubicin (DXR) were generous gifts from
Alza Corp. (Mountain View, CA). Maleimide-deriv-
atized PEG2000-DSPE (Mal-PEG-DSPE) [27] was
custom synthesized by Shearwater Polymers (Hunts-
ville, AL). Cholesterol (CHOL) and dioleoylphos-
phatidylethanolamine (DOPE) were purchased from
Avanti Polar Lipids (Alabaster, AL). N-[2-g-methoxy-
poly(ethylene glycol)-K aminocarbonyl-ethyl-dithio-
propionyl]-DSPE (mPEG-S-S-DSPE, disul¢de-link-
er) was synthesized as described elsewhere [25].
Sephadex G-50 and Sepharose CL-4B were pur-
chased from Pharmacia Biotech (Uppsala, Sweden).
Na125I and cholesteryl-[1,2-[3H](N)]-hexadecyl ether
([3H]CHE) were purchased from Mandel Scienti¢c
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(Guelph, ON). Cholesteryl hemisuccinate (CHEMS),
3-(4,5-dimethylthiazol-2-ly)-2,5-diphenyltetrazolium
bromide (MTT) and iminothiolane were purchased
from Sigma Chemicals (Oakville, ON). p-Xylene-
bis-pyridinium bromide (DPX) and trisodium 8-hy-
droxypyrenetrisulfonate (HPTS) were purchased
from Molecular Probes (Eugene, OR). Iodination
of IgG was performed according to the method de-
scribed elsewhere [4]. Tyraminylinulin (TI) synthesis
and preparation of [125I]TI have been described pre-
viously [28]. The murine monoclonal antibody (mAb)
anti-CD19 was prepared from the FMC-63 murine
anti-CD19 hybridoma cell line obtained from Dr. H.
Zola (Children’s Health Research Institute, Austra-
lia). The human B-lymphoma cell line Namalwa
(ATCC CRL 1432) was obtained from American
Type Culture Collection (MD, USA). Human plas-
ma was obtained from healthy volunteers at the Uni-
versity of Alberta, Department of Pharmacology.
Nuclepore polycarbonate membranes (0.08, 0.1 and
0.2 Wm pore size) were purchased from Northern
Lipids (Vancouver, BC). All other chemicals were
of analytical grade.
2.2. Preparation of liposomes
Sterically stabilized pH-sensitive liposomes were
prepared from a mixture of DOPE or DOPE/
CHEMS (6:4 molar ratio) and either mPEG-DSPE
or mPEG-S-S-DSPE. The lipid molar ratios of the
di¡erent formulations are indicated in the text or in
Table or Figure legends. SIL (not pH-sensitive) for
coupling to anti-CD19 were composed of HSPC/
CHOL/mPEG-DSPE/Mal-PEG-DSPE,
2:1:0.08:0.02. Brie£y, chloroform solutions of lipids
were mixed and the solvent was evaporated using a
rotary evaporator; residual solvent was removed
under high vacuum. The dried lipid ¢lms were hy-
drated with an appropriate bu¡er and sequentially
extruded through a series of polycarbonate ¢lters
with pore sizes ranging from 0.2 to 0.08 Wm, using
a Lipex Extruder (Lipex Biomembranes, Vancouver,
BC). The mean diameter of liposomes was deter-
mined by dynamic light scattering using a Brook-
haven BI-90 Particle Sizer (Brookhaven Instruments,
Holtsville, NY). The diameters of extruded lipo-
somes were in the range of 120 þ 10 nm. For lipo-
somes loaded with either HPTS-DPX or [125I]TI, the
lipid ¢lms were hydrated with HPTS-DPX solution
(30 mM HPTS, 30 mM DPX, pH 9.0, adjusted to
290 mosmol with NaCl) or [125I]TI solution (pH 9.0).
Following extrusion, the untrapped dye or [125I]TI
was removed by chromatography on Sephadex G-
50 or Sepharose CL-4B columns, respectively, eluted
with HEPES bu¡er (25 mM HEPES, 140 mM
NaCl), pH 7.4.
DXR-SIL[anti-CD19] were prepared and DXR
loaded by the ammonium sulfate loading method at
65‡C as previously described [4]. The lipid molar
ratios of the additional targeted formulations of lipo-
somal DXR, composed of DXR-DOPE/mPEG-
DSPE[anti-CD19], DXR-DOPE/CHEMS/mPEG-
DSPE[anti-CD19], DXR-DOPE/mPEG-S-S-DSPE-
[anti-CD19], or DXR-DOPE/CHEMS/mPEG-S-S-
DSPE[anti-CD19] are indicated in the text or in
Table or Figure legends; the drug was encapsulated
by remote loading using an ammonium sulfate gra-
dient [29] with minor modi¢cations. Brie£y, the lipid
¢lms were hydrated in 250 mM ammonium sulfate at
pH 8.5 for formulations containing DOPE/CHEMS/
PEG-DSPE or at pH 9.0 for formulations containing
DOPE/PEG-DSPE, with addition of minute amounts
of NaOH until complete hydration was obtained.
Following extrusion, the external bu¡er was ex-
changed by eluting through a Sephadex G-50 column
equilibrated with 10% sucrose, 25 mM Trizma base
at pH 8.5 or pH 9.0, as appropriate. The higher pH
was necessary to get DOPE formulations to self-as-
semble into bilayers [16,30]. DXR was added to the
liposomes at a DXR/PL ratio of 0.2:1 (w/w), and the
liposomes were incubated for 15 min at 22‡C. The
liposome-encapsulated DXR was separated from free
DXR by chromatography on a Sephadex G-50 col-
umn eluted with degassed HEPES bu¡er. Coupling
of anti-CD19 mAb to Mal-PEG-DSPE on the lipo-
somes was carried out according to a previously de-
scribed method [15], using 125I-labeled anti-CD19
mAb as a tracer. The concentration of liposome-en-
trapped DXR was determined by spectrophotometry
(V= 490 nm) following methanol extraction. Phos-
pholipid concentrations were determined using the
Fiske^Subbarow colorimetric assay [31]. All mAb
densities were routinely in the range of 30^60 Wg
anti-CD19/Wmol PL for in vivo experiments and
65^80 Wg anti-CD19/Wmol PL for in vitro experi-
ments.
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2.3. In vitro leakage experiments
Liposomes containing either entrapped HPTS-
DPX or DXR were passed over a Sephadex G-50
column immediately prior to use to remove any re-
sidual free dye or drug. The release of entrapped
solute was studied using a £uorescence-dequenching
assay. Fifty Wl of liposomes containing entrapped dye
(HPTS-DPX) or DXR were incubated at 0.5 mM
¢nal PL concentration at 37‡C in 450 Wl of various
pH bu¡ers, cell-free extract (CFE), human plasma,
or cell-culture medium containing 10% fetal bovine
serum (FBS). At various time points, the percentage
of released HPTS was determined in an aliquot of
the incubation mixture by the increase in sample
£uorescence at an emission wavelength of 512 nm
and an excitation wavelength of 413 nm [32] relative
to that of the pre-incubation sample (zero release)
using an SLM-Aminco Model 8100 £uorimeter
(Spectronic Instruments, Rochester, NY); values
were normalized to the increase in £uorescence ob-
tained after lysis of a pre-incubation sample with
10% Triton X-100 [25]. The £uorescence of DXR
contained in liposomes was quenched due to its
self-association when loaded by the ammonium sul-
fate method; DXR leakage was determined by £uo-
rescence dequenching at excitation and emission
wavelengths of 485 and 590 nm, respectively. Lipo-
somes were incubated at 37‡C with various bu¡ers,
CFE, cell-culture medium containing 10% FBS, or
human plasma. At designated intervals, aliquots
were taken, and the amount of released DXR was
determined as described above. Total DXR (100%
dequenched) was measured by lysing the liposomes
at a ¢nal Triton X-100 concentration of 0.5% (v/v).
2.4. Preparation of cell-free extracts
Namalwa cells were maintained in logarithmic
growth conditions in RPMI 1640 supplemented
with 10% FBS at 37‡C in a humidi¢ed atmosphere
containing 5% CO2. Cells (1.0U108) were collected
by centrifugation (1000 rpm for 10 min) and washed
with 20 ml of TEA bu¡er (10 mM triethanolamine,
0.25 M sucrose, 10 mM acetic acid, and 1 mM
EDTA, pH 7.4). The washed cells were resuspended
in 4 ml TEA bu¡er and a protease inhibitor cocktail
formulated for mammalian cell extracts (4-(2-amino-
ethyl)-benzenesulfonyl £uoride, pepstatin A, trans-
epoxysuccinyl-L-leucylamino(4-guanidino)butane,
bestatin, leupeptin, and aprotinin; Sigma, MO,
USA) was added at 100 Wl per gram of cells. The
cells were ruptured at 4‡C using 40 ¢rm strokes
with a tight-¢tting Dounce homogenizer. Unbroken
cells were pelleted by centrifugation at 1000 rpm for
10 min at 4‡C. The CFE was carefully removed from
the cell pellet and then diluted to 6 ml with the ad-
dition of TEA bu¡er.
2.5. Nuclear accumulation assay
Nuclear accumulation of DXR was determined ac-
cording to the method of Kirchmeier et al. [33].
Brie£y, 4.5U108/500 ml Namalwa cells, maintained
under logarithmic growth conditions in RPMI 1640
supplemented with 10% FBS, were treated with var-
ious DXR formulations at a DXR concentration of
8 WM. At various time points (0, 2, 4, 8, 12 h), 100 ml
of cells were pelleted by centrifugation at 1000 rpm
for 10 min and washed with 20 ml of TEA bu¡er.
Washed cells were resuspended in 3 ml TEA bu¡er
and ruptured at 4‡C using 40 ¢rm strokes with a
tight-¢tting Dounce homogenizer. Unbroken cells
were pelleted and the CFE, which contained the nu-
clei, was carefully removed from the cell pellet. To
obtain more complete homogenization, the pellet of
unbroken cells was suspended in TEA bu¡er (3 ml)
and ruptured a second time, followed again by re-
moval of the unbroken cells. The combined super-
natants were centrifuged at 1000 rpm for 10 min to
remove any remaining unbroken cells. The superna-
tant from this centrifugation step was spun at 2000
rpm for 2.5 min at 4‡C to pellet nuclei. After remov-
al of the supernatant, the pellet was diluted to 1 ml
with TEA bu¡er, then vortexed and sonicated until
the nuclei were evenly dispersed, as determined by
visual inspection.
For each time point, three aliquots of the nuclear
fractions (0.2 ml each) were placed in 1.3 ml TEA.
DNA was enzymatically digested by the addition of
10 Wl digitonin solution (25 mg/ml in sterile PBS,
Sigma, St. Louis, MO), 10 Wl MgCl2 solution (57
mg/ml in sterile PBS) and 50 Wl DNase 1 solution
(3 mg/ml in sterile PBS, Sigma). Following digestion
at 22‡C for 2 h, the DXR £uorescence was recorded
(excitation at 480 nm and emission at 595 nm). The
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purity of the nuclear fraction was checked by deter-
mining the levels of enzyme markers for various cel-
lular organelles [15].
2.6. In vitro cytotoxicity experiments
A comparison of the in vitro cytotoxicity of free
DXR and various liposomal formulations was per-
formed on Namalwa cells with an in vitro prolifer-
ation assay using a tetrazolium dye (MTT) [34], as
described in [4].
2.7. Blood elimination of liposomes in BALB/c
(inbred) mice
Female BALB/c Cr Alt B/M mice, in the weight
range of 17^22 g, were obtained from University of
Alberta Health Sciences Laboratory Animal Services,
and were injected via the tail vein with a single bolus
dose of 0.2 ml of liposomes of various formulations
containing encapsulated [125I]TI (0.5 Wmol PL/
mouse). At selected times post-injection, mice were
anesthetized with halothane and sacri¢ced by cervical
dislocation. A blood sample (100 Wl) was collected by
cardiac puncture. Blood samples, various organs and
the carcass were counted for 125I label in a Beckman
8000 gamma counter. Data were analyzed using
PKAnalyst (MicroMath Scienti¢c Software).
2.8. In vivo therapeutic experiments
Namalwa cells were passaged i.p. in CB.-17/ICR
Tac SCID mice (Charles River Laboratories, Que-
bec, Canada) to develop a more virulent strain with
reproducible tumor take [4]. Namalwa cells were har-
vested in sterile PBS and implanted into SCID mice.
Cell viability was assessed by dye exclusion using
Trypan Blue dye before and after the implantation
process. For therapeutic experiments, CB-17/ICR
Tac SCID mice (Charles River Laboratories), 6^8
weeks of age, were injected with cells i.v. (5U106)
and treated i.v. at 24 h after implantation with a
single dose of 3 mg DXR/kg as either free DXR,
DXR-SIL[anti-CD19] or targeted DXR-loaded
DOPE/CHEMS formulations stabilized with either
mPEG-DSPE or mPEG-S-S-DSPE. Mice were moni-
tored routinely for weight loss, and euthanized as
they became moribund; survival times were re-
corded. All animal experiments were approved by
the Health Sciences Animal Policy and Welfare
Committee of the University of Alberta (Edmonton,
Alberta, Canada).
2.9. Statistics
Statistical analyses were performed using Graph-
Pad Instat software (v.3.01, GraphPad Software, San
Diego, CA) using analysis of variance for multiple
comparisons. Data were considered signi¢cant at
P6 0.05.
3. Results
3.1. pH sensitivity of liposomal HPTS in bu¡er
Leakage of HPTS from DOPE (Fig. 1) and
DOPE/CHEMS (Fig. 2) liposomes, stabilized with
mPEG-DSPE (Fig. 1A and 2A) or mPEG-S-S-
DSPE (Fig. 1B and 2B), was examined as a function
of pH and reducing conditions. At physiological pH
and ionic strength, DOPE does not form bilayers,
but rather exists in an inverted hexagonal (HII) phase
[17]. However, DOPE will form liposomes readily at
higher pH, upon deprotonation of the amine group.
Dilution of DOPE liposomes, made at pH 8.5^9.0,
into pH 7.4 or pH 5.5 bu¡ers led to rapid release of
contents (Fig. 1A). Incorporation of 5 mol% mPEG-
DSPE (Fig. 1A) or mPEG-S-S-DSPE (Fig. 1B) into
DOPE liposomes resulted in the formation of lipo-
somes which did not leak at physiological or acid pH
over 24 h. Treatment of liposomes with dithiothreitol
(DTT) was used to induce thiolytic cleavage of
mPEG-S-S-DSPE from the lipid membrane anchor
(DSPE) in liposomes containing mPEG-S-S-DSPE
(Fig. 1B). DOPE liposomes containing 5 mol%
mPEG-S-S-DSPE had little contents release over 24 h
in the presence of DTT at pH 7.4 (Fig. 1B); however
at pH 5.5, treatment with DTT led to a gradual
release of HPTS (50% release in about 10 h). At pH
5.5, a DOPE formulation that contained 3 mol%
mPEG-S-S-DSPE had a much more rapid release
of contents (100% release in 2 h, data not shown).
DOPE liposomes can also be stabilized in the bi-
layer state by an amphiphile with bulky and/or
charge-repulsing hydrophilic moieties [35]. CHEMS
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(cholesteryl hemisuccinate), which is net negatively
charged at pH 7.4, has been widely used to stabilize
DOPE in the bilayer state at neutral pH. Protonation
of CHEMS at low pH (6 6.0) accelerates the desta-
bilization of DOPE vesicles by promoting the forma-
tion of the hexagonal (HII) phase [16,36]. DOPE/
CHEMS formulations without mPEG-DSPE had lit-
tle leakage at pH 7.4, but rapidly released encapsu-
lated dye at pH 5.5 (Fig. 2A). At pH 5.5 or 7.4 less
than 10% leakage occurred over 24 h when these
liposomes were stabilized with 5 mol% mPEG-
DSPE (Fig. 2A). In the presence of DTT, DOPE/
Fig. 2. Leakage of encapsulated HPTS from DOPE/CHEMS
formulations þ mPEG-DSPE or mPEG-S-S-DSPE in bu¡ers of
varying pH at 37‡C ( þ DTT). HPTS encapsulated in DOPE/
CHEMS formulations stabilized with various PEG-DSPE con-
jugates (cleavable or non-cleavable) at pH 9.0 were diluted into
bu¡er at either pH 7.4 or pH 5.5, at 37‡C. Incubation with
DTT, determination of released £uorescence and determination
of released HPTS were as described in the legend for Fig. 1.
The formulations consisted of DOPE/CHEMS alone (6:4 molar
ratio), or DOPE/CHEMS/mPEG-DSPE or DOPE/CHEMS/
mPEG-S-S-DSPE, 6:4:0.3 molar ratio. Results are from a rep-
resentative experiment, and are means of triplicate analy-
ses þ S.D. (A) b, DOPE/CHEMS, no mPEG-DSPE, pH 7.4; a,
DOPE/CHEMS, no mPEG-DSPE, pH 5.5; R, DOPE/CHEMS/
mPEG-DSPE, pH 7.4; O, DOPE/CHEMS/mPEG-DSPE, pH
5.5. (B) F, DOPE/CHEMS/mPEG-S-S-DSPE, pH 7.4; S,
DOPE/CHEMS/mPEG-S-S-DSPE, pH 5.5; E, DOPE/CHEMS/
mPEG-S-S-DSPE+DTT, pH 7.4; P, DOPE/CHEMS/mPEG-S-
S-DSPE+DTT, pH 5.5.
Fig. 1. Leakage of encapsulated HPTS from DOPE formula-
tions þ mPEG-DSPE or mPEG-S-S-DSPE in bu¡ers of varying
pH at 37‡C ( þ DTT). HPTS encapsulated in DOPE stabilized
with various PEG-DSPE conjugates (cleavable or non-cleavable)
at pH 9.0 was diluted into bu¡er at either pH 7.4 or pH 5.5, at
37‡C. Formulations containing mPEG-S-S-DSPE were also in-
cubated with DTT (100 mM) at pH 7.4 or pH 5.5. At speci¢ed
time points, aliquots were added to HEPES bu¡er (pH 7.4) and
the £uorescence intensity of the sample was determined using a
spectro£uorimeter. Released HPTS was determined as the per-
centage increase in the sample £uorescence over that of the pre-
incubation sample treated with Triton X-100 (100% release).
The formulations consisted of DOPE, or DOPE/mPEG-DSPE,
or DOPE/mPEG-S-S-DSPE, 1:0.05 molar ratio. Results are
from a representative experiment, and are means of triplicate
analyses þ S.D. (error bars are smaller than markers in many
cases). (A) b, DOPE, no PEG-DSPE, pH 7.4; a, DOPE, no
PEG-DSPE, pH 5.5; R, DOPE/mPEG-DSPE, pH 7.4; O,
DOPE/mPEG-DSPE, pH 5.5. (B) F, DOPE/mPEG-S-S-DSPE,
pH 7.4; S, DOPE/mPEG-S-S-DSPE, pH 5.5; E, DOPE/
mPEG-S-S-DSPE+DTT, pH 7.4; P, DOPE/mPEG-S-S-DSPE+
DTT, pH 5.5.
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CHEMS liposomes containing 5 mol% mPEG-S-S-
DSPE had a release half-life of approximately 8 h
at pH 5.5, while little release occurred at pH 7.4
(Fig. 2B); DTT treatment of DOPE/CHEMS lipo-
somes stabilized with 3 mol% mPEG-S-S-DSPE re-
sulted in intermediate leakage rates (data not
shown).
3.2. Release of liposomal HPTS by cell-free extracts
(CFE)
Since CFE is expected to contain cytoplasmic and
lysosomal enzymes, the leakage of the hydrophilic,
membrane-impermeable dye HPTS from formula-
tions exposed to CFE may mimic the process of de-
stabilization, in an intracellular environment, of lipo-
somes stabilized with either mPEG-DSPE or mPEG-
S-S-DSPE. CFE was adjusted to pH 5.5, approxi-
Fig. 4. Leakage in human plasma of encapsulated DXR from
DOPE or DOPE/CHEMS formulations containing mPEG-
DSPE or mPEG-S-S-DSPE. DOPE or DOPE/CHEMS lipo-
somes, containing mPEG-DSPE or mPEG-S-S-DSPE, with
anti-CD19 as a targeting moiety, were incubated in human
plasma (pH 7.4) at 37‡C. At speci¢ed time points, aliquots
were collected from the incubation mixture, and diluted in
HEPES bu¡er (pH 7.4), the £uorescence intensity of the sample
was determined using a spectro£uorimeter, and released DXR
was determined as the percentage increase in the sample £uores-
cence over that of samples preincubated with Triton X-100. Re-
sults are from a representative experiment, and are means of
triplicate analyses þ S.D. (A) b, anti-CD19-targeted, DXR-
loaded DOPE/mPEG-DSPE/Mal-PEG-DSPE (1:0.04:0.01);
R, anti-CD19-targeted, DXR-loaded DOPE/CHEMS/mPEG-
DSPE/Mal-PEG-DSPE (6:4:0.2:0.1). (B) F, anti-CD19-tar-
geted, DXR-loaded DOPE/mPEG-S-S-DSPE/Mal-PEG-DSPE
(1:0.04:0.01); S, anti-CD19-targeted, DXR-loaded DOPE/
CHEMS/mPEG-S-S-DSPE/Mal-PEG-DSPE (6:4:0.2:0.1).
Fig. 3. Leakage of encapsulated HPTS from formulations þ m-
PEG-S-S-DSPE in cell-free extract. DOPE liposomes (A) or
DOPE/CHEMS liposomes (B) containing encapsulated HPTS,
and di¡erent proportions of mPEG-S-S-DSPE in the lipid mix,
were incubated in cell-free extract adjusted to pH 5.5 at 37‡C.
The £uorescence intensity of the sample and the percentage of
released HPTS were determined as described in the legend of
Fig. 1. Results are from a representative experiment, and are
means of triplicate analyses þ S.D. (A) b, DOPE alone; R,
DOPE/mPEG-S-S-DSPE (1:0.03); F, DOPE/mPEG-S-S-DSPE
(1:0.05). (B) a, DOPE/CHEMS (6:4); O, DOPE/CHEMS/
mPEG-S-S-DSPE (6:4:0.18); E, DOPE/CHEMS/mPEG-S-S-
DSPE (6:4:0.3).
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mating the lysosomal pH of between 5 and 6.5
[37,38]. DOPE formulations, or DOPE formulations
with 3 mol% mPEG-S-S-DSPE, released their con-
tents in CFE with half-lives of 1.7 h (Fig. 3A). The
release rate in CFE of the DOPE formulation with
5 mol% mPEG-S-S-DSPE was considerably slower;
only 40% of encapsulated dye was released over 24 h
(Fig. 3A). All three DOPE/CHEMS formulations,
with or without mPEG-S-S-DSPE, released HPTS
rapidly in CFE at pH 5.5; this release was almost
complete by 8 h (Fig. 3B). DOPE/CHEMS and
DOPE/CHEMS/mPEG-S-S-DSPE formulations in-
cubated in CFE adjusted to pH 7.4 released HPTS
at much slower rates (data not shown).
3.3. Leakage of HPTS or DXR from pH-sensitive
liposomes incubated in human plasma
Having evaluated the leakage rates of the hydro-
philic compound HPTS from various liposome for-
mulations in bu¡er or CFE, we proceeded to evalu-
ate leakage in 90% human plasma at 37‡C. The
chemical structure of the loaded drug will have an
e¡ect on the rate of its leakage from a liposome
formulation. HPTS is passively loaded into lipo-
somes as the water-soluble (but £uorescence-
quenched) complex, HPTS-DPX. When HPTS-
DPX leaks from liposomes, it dissociates into free
HPTS and DPX, increasing the HPTS £uorescence
when excited at 413 nm. Less than 20% of encapsu-
lated HPTS leaked from DOPE/mPEG-DSPE,
DOPE/CHEMS/mPEG-DSPE, DOPE/mPEG-S-S-
DSPE or DOPE/CHEMS/mPEG-S-S-DSPE formu-
lations over 24 h in human plasma (not shown).
Doxorubicin is normally actively loaded into lipo-
somes at a pH of about 5.5, using an ammonium
sulfate gradient, resulting in the precipitation of a
(DXR-NH3)2SO4 gel inside the liposomes [29]. How-
ever, at the higher pH required to assemble DOPE/
CHEMS/PEG-DSPE into liposomes, it is not known
whether DXR forms a precipitate inside liposomes
during active loading, and this may a¡ect the rate
at which DXR leaks from these pH-sensitive lipo-
somes. The leakage of DXR in human plasma was
examined for anti-CD19-targeted liposomes of
DOPE/mPEG-DSPE, DOPE/CHEMS/mPEG-DSPE
(Fig. 4A), DOPE/mPEG-S-S-DSPE or DOPE/
CHEMS/mPEG-S-S-DSPE (Fig. 4B) liposomes.
There was rapid leakage of DXR from all formula-
tions with the exception of DOPE/CHEMS/mPEG-
DSPE, which had a somewhat slower (but still rapid)
leakage rate (Fig. 4A). There was no signi¢cant dif-
ference in the rate of DXR release between the anti-
CD19-targeted and similar non-targeted formula-
tions (containing 5 mol % mPEG) in the presence
of human plasma (data not shown).
Before using these liposomes in cell-culture experi-
ments, we also examined whether anti-CD19-targeted
DXR-loaded formulations of the same lipid compo-
sitions described in the previous paragraph were sta-
Table 1
Cytotoxicity of free doxorubicin (DXR) and liposomal formulations of DXR (with or without anti-CD19) to CD19 Namalwa cells
Formulation of DXR-loaded liposomes IC50 (WM DXR)
DOPE/mPEG-DSPE (1:0.05) 7.0 þ 2.2
DOPE/mPEG-DSPE/Mal-PEG-DSPE[anti-CD19] (1:0.04:0.01) 0.2 þ 0.1
DOPE/mPEG-S-S-DSPE (1:0.03) 8.9 þ 4.7
DOPE/mPEG-S-S-DSPE/Mal-PEG-DSPE[anti-CD19] (1:0.02:0.01) 1.5 þ 0.7
DOPE/CHEMS/mPEG-DSPE (6:4:0.3) 4.2 þ 1.1
DOPE/CHEMS/mPEG-DSPE/Mal-PEG-DSPE[anti-CD19] (6:4:0.24:0.06) 0.4 þ 0.1
DOPE/CHEMS/mPEG-S-S-DSPE (6:4:0.18) 6.0 þ 0.8
DOPE/CHEMS/mPEG-S-S-DSPE/Mal-PEG-DSPE[anti-CD19] (6:4:0.12:0.06) 3.3 þ 1.0
HSPC/CHOL/mPEG-DSPE s 200
HSPC/CHOL/mPEG-DSPE/Mal-PEG-DSPE[anti-CD19] (2:1:0.08:0.02) 35.4 þ 12.7
Free DXR 0.8 þ 0.7
Namalwa cells (5U105) were incubated with free DXR or various formulations of liposome-encapsulated DXR with or without anti-
CD19 mAb. mAb coupling via the PEG-Maleimide method was 65^80 Wg mAb/Wmol PL; DXR loading was 140^160 Wg DXR/Wmol
PL (0.24^0.28 Wmol DXR/Wmol PL). After 1 h, cells were washed free of drug and then incubated for a further 48 h. Cytotoxicities
were determined by the MTT assay and are expressed as mean IC50 þ S.D. (n = 3^6).
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ble in cell culture media containing 10% FBS at
37‡C. Over 24 h there was less than 10% DXR leak-
age (data not shown).
3.4. In vitro cytotoxicity of targeted, PEG-DSPE-
stabilized, pH-sensitive liposomes
We compared the cytotoxicity of anti-CD19-tar-
geted DOPE or DOPE/CHEMS formulations of
liposomal DXR, stabilized with either mPEG-
DSPE or mPEG-S-S-DSPE, to the cytotoxicity for
non-targeted formulations stabilized with mPEG-
DSPE or mPEG-S-S-DSPE, and to DXR-SL,
DXR-SIL[anti-CD19] or free DXR (Table 1). All
the DOPE or DOPE/CHEMS formulations, either
targeted or non-targeted, had signi¢cantly lower
IC50s than the DXR-SL or DXR-SIL[anti-CD19]
formulations (P6 0.001). Possibly this is because
the overall release rates of DXR from the DOPE
or DOPE/CHEMS formulations (Figs. 1^4) are high-
er than the release rates of DXR from DXR-SL or
DXR-SIL[anti-CD19], which have a negligible re-
lease of drug on the time scale of our experiments
[4]. Targeted DOPE and DOPE/CHEMS formula-
tions had IC50s that were comparable in most instan-
ces to those for free DXR (Table 1). The IC50s of
DXR-loaded targeted formulations of either DOPE
or DOPE/CHEMS (stabilized with mPEG-DSPE or
mPEG-S-S-DSPE) were signi¢cantly lower than the
IC50s of the non-targeted formulations (P6 0.05 to
P6 0.001). Notably, there was a trend for formula-
tions that contained mPEG-DSPE to be slightly
more cytotoxic than those that contained mPEG-S-
S-DSPE, whether targeted or non-targeted. Targeted
formulations without encapsulated DXR were not
toxic at concentrations below 0.06 WM DOPE, which
would correspond to a DXR concentration of 34.5
WM, if the formulations contained DXR (not
shown).
3.5. Nuclear accumulation of doxorubicin within
Namalwa cells
In theory, the rate of release of encapsulated DXR
from the lysosomal apparatus, following internaliza-
tion of targeted liposomes, is a determining factor in
the cytotoxicity of liposome-encapsulated DXR. To
demonstrate the kinetics of release of DXR from the
Fig. 5. In vitro nuclear accumulation of doxorubicin in Namal-
wa cells. The DXR nuclear accumulation assay is as described
in Section 2. Results are from a representative experiment, and
are means of triplicate analyses þ S.D. (A) b, free DXR;
F, DXR-HSPC/CHOL/mPEG-DSPE, 2:1:0.1; R, anti-CD19 tar-
geted DXR-HSPC/CHOL/mPEG-DSPE/Mal-PEG-DSPE, 2:1:
0.08:0.02. (B) b, anti-CD19-targeted DXR-DOPE/mPEG-
DSPE/Mal-PEG-DSPE, 1:0.04:0.01; R, anti-CD19 targeted
DXR-DOPE/CHEMS/mPEG-DSPE/Mal-PEG-DSPE, 6:4:0.24:
0.06; a, DXR-DOPE/mPEG-DSPE, 1:0.05; O, DXR-DOPE/
CHEMS/mPEG-DSPE, 6:4:0.3. (C) S, anti-CD19 targeted
DXR-DOPE/CHEMS/mPEG-S-S-DSPE/Mal-PEG-DSPE, 6:4:
0.12:0.06; F, anti-CD19-targeted DXR-DOPE/mPEG-S-S-
DSPE/Mal-PEG-DSPE, 1:0.02:0.01; E, non-targeted DXR-
DOPE/mPEG-S-S-DSPE, 1:0.03; P, non-targeted DXR-
DOPE/CHEMS/mPEG-S-S-DSPE, 6:4:0.18.
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endosomes, the rate of accumulation of DXR in cell
nuclei was determined by using a DXR nuclear ac-
cumulation assay (Fig. 5). For each formulation,
DXR was detectable in the nuclear fraction of cells
after 2 or 3 h incubation. As expected in this in vitro
assay, free DXR accumulated within the nuclei at the
fastest rate (Fig. 5A). Rates of DXR release for tar-
geted mPEG-DSPE-stabilized (Fig. 5B) or mPEG-S-
S-DSPE-stabilized (Fig. 5C) DOPE or DOPE/
CHEMS formulations were much faster than that
of targeted DXR-SIL[anti-CD19] (Fig. 5A). The or-
der of nuclear accumulation of DXR from liposomal
formulations was: free drugs targeted mPEG-S-S-
DSPEs targeted mPEG-DSPEsnon-targeted mPE-
G-S-S-DSPEs non-targeted mPEG-DSPEs tar-
geted DXR-SILs SL. Interestingly, although they
were not more cytotoxic than mPEG-containing for-
mulations (Table 1), formulations containing mPEG-
S-S-DSPE appeared to result in more rapid nuclear
accumulations of DXR over the time course of these
experiments (Fig. 5).
3.6. Blood elimination of PEG-DSPE-stabilized
pH-sensitive liposomes
In order to determine the pharmacokinetics of the
Fig. 6. Pharmacokinetics of DOPE or DOPE/CHEMS liposomes in BALB/c mice. Female BALB/c mice were injected i.v. via the tail
vein with a single dose of 0.2 ml of [125I]TI encapsulated in various liposomal formulations (0.5 Wmol PL/mouse). At selected times
after injection blood samples were collected and counted for 125I. Results are from a representative experiment, and are means of trip-
licate analyses þ S.D. (A) 8, DOPE; F, DOPE/mPEG-DSPE, 1.0:0.03; R, DOPE/mPEG-DSPE, 1.0:0.05; b, DOPE/mPEG-DSPE,
1.0:0.1. (B) 7, DOPE/CHEMS; E, DOPE/CHEMS/mPEG-DSPE, 6:4:0.18; O, DOPE/CHEMS/mPEG-DSPE, 6:4:0.3; a, DOPE/
CHEMS/mPEG-DSPE, 6:4:0.6. (C) F, DOPE/mPEG-S-S-DSPE/mPEG-DSPE, 1.0:0.02:0.01; R, DOPE/mPEG-S-S-DSPE/mPEG-
DSPE, 1.0:0.04:0.01; b, DOPE/mPEG-S-S-DSPE/mPEG-DSPE, 1.0:0.09:0.01. (D) E, DOPE/CHEMS/mPEG-S-S-DSPE/mPEG-
DSPE, 6:4:0.012:0.06; O, DOPE/CHEMS/mPEG-S-S-DSPE/mPEG-DSPE, 6:4:0.024:0.06; a, DOPE/CHEMS/mPEG-S-S-DSPE/
mPEG-DSPE, 6:4:0.054:0.06.
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liposome preparations, liposomes containing radiola-
beled [125I]TI were prepared and injected into the tail
vein of mice at a PL dose of 0.5 Wmol/mouse. Circu-
lation times increased with increasing concentration
of mPEG-DSPE in either DOPE or DOPE/CHEMS
liposome formulations (Fig. 6A,B). Approximately
5^10% of the injected liposomes still remained in
the blood 24 h after injection of liposomes containing
10 mol% mPEG-DSPE. Injection of DOPE or
DOPE/CHEMS liposomes that were not stabilized
with mPEG-DSPE resulted in rapid clearance of
the liposomes. Liposomes accumulated primarily in
the liver and spleen (not shown). Inclusion of from
2 to 9 mol% of mPEG-S-S-DSPE did not increase the
circulation times for either the DOPE (Fig. 6C) or
DOPE/CHEMS (Fig. 6D) formulations. All mPEG-
S-S-DSPE formulations contained 1 mol% mPEG-
DSPE to mimic the e¡ect of adding 1 mol% coupling
lipid to the formulations in targeting experiments.
Increasing amounts of mPEG-S-S-DSPE in the for-
mulations did not increase circulation half-lives of
the formulations to any signi¢cant extent (Fig.
6A,B), likely because the mPEG-S-S-DSPE was rap-
idly cleaved in plasma.
3.7. In vivo therapeutic experiments
For therapeutic experiments, SCID mice (5 mice/
group), implanted i.v. with 5U106 Namalwa cells,
were treated i.v. at 24 h after implantation with sin-
gle doses of 3 mg/kg free DXR or liposome-encapsu-
lated DXR (Table 2). No evidence of drug toxicity
was observed in any experimental group. None of
the non-targeted DXR-loaded formulations showed
improved therapeutic e⁄cacy over the control group
(Ps 0.05). All groups treated with targeted formula-
tions had signi¢cantly higher increased life spans
(%ILS) than did the control group or groups treated
with non-targeted formulations (P6 0.001). The
group treated with DXR-DOPE/CHEMS/mPEG-S-
S-DSPE/Mal-PEG-DSPE[anti-CD19] had a signi¢-
cantly increased %ILS compared to the other tar-
geted treatment groups (vs. DXR-DOPE/CHEMS/
mPEG-DSPE/Mal-PEG-DSPE[anti-CD19], P6
0.001; vs. DXR-SIL[anti-CD19], P6 0.01).
4. Discussion
Ligand-mediated targeting of drug carrier systems
like SIL can improve site-speci¢c drug delivery [4^
14]. We have previously demonstrated that the tar-
geting of DXR-SIL[anti-CD19] to CD19, an inter-
nalizing epitope expressed on cells of B-cell lineage,
increases its therapeutic index against B-cell-derived
haematological malignancies [4,39]. In this study we
have attempted to further increase the e⁄cacy of
anti-CD19-targeted liposomal formulations of DXR
by increasing the rate of intracellular drug release
through the strategy of employing pH-sensitive tar-
Table 2
In vivo survival studies with triggered release formulations in SCID mice bearing CD19 human B-lymphoma (Namalwa) cells
Treatment MST þ S.D.(days) % ILS
Saline 21.0 þ 1.6 ^
Free DXR 23.0 þ 1.4 9.5
DOPE/CHEMS/mPEG-DSPE 27.8 þ 1.6 32.4
DOPE/CHEMS/mPEG-S-S-DSPE 25.8 þ 4.0 22.9
HSPC/CHOL/mPEG-DSPE 24.2 þ 1.3 15.2
DOPE/CHEMS/mPEG-DSPE[anti-CD19] 42.2 þ 4.1 101
DOPE/CHEMS/mPEG-S-S-DSPE[anti-CD19] 53.8 þ 6.5 156.2
HSPC/CHOL/mPEG-DSPE[anti-CD19] 43.2 þ 5.7 105.7
SCID mice were implanted i.v. with 5U106 cells, then injected i.v. 24 h later with either saline, free DXR, or DXR-loaded in either
anti-CD19 targeted or non-targeted, mPEG-DSPE-stabilized or mPEG-S-S-DSPE-stabilized formulations composed of HSPC/CHOL/
mPEG-DSPE/Mal-PEG-DSPE (2:1:0.08:0.02) or DOPE/CHEMS/mPEG-DSPE/Mal-PEG-DSPE (6:4:0.24:0.06) or DOPE/CHEMS/
mPEG-S-S-DSPE/Mal-PEG-DSPE (6:4:0.24:0.06). Liposomes composed of DOPE/CHEMS/mPEG-DSPE/Mal-PEG-DSPE, DOPE/
CHEMS/mPEG-S-S-DSPE/Mal-PEG-DSPE, or HSPC/CHOL/mPEG-DSPE/Mal-PEG-DSPE contained 33.3, 31.2 or 58.4 Wg anti-
CD19/Wmol PL, respectively. All treatment groups received DXR 3 mg/kg. MST, mean survival time; ILS, increased life span over
MST of control.
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geted liposomes. Liposomes exhibiting pH sensitivity
have been described previously, but their potential
for use in vivo has been hampered by their rapid
removal from circulation into the MPS. Although
inclusion of mPEG-DSPE into pH-sensitive,
DOPE-containing liposome formulations increased
both the stability and the circulation half-lives of
the liposomes, these liposomes did not destabilize
at low pH, as determined by an in vitro dye release
assay [23^25]. Theoretically, this loss of pH sensitiv-
ity could be avoided through the incorporation of
cleavable PEG-lipid derivatives into the formula-
tions. As previously reported, addition of 3 mol%
of a thiol cleavable PEG-derivative, mPEG-S-S-
DSPE, signi¢cantly increased the stability of DOPE
or DOPE/CHEMS formulations in vitro; the pH-de-
pendent leakage of HPTS was restored by treatment
with a thiolytic agent, DTT, which cleaves the PEG
chains from mPEG-S-S-DSPE [25].
At physiological pH, DOPE is in the HII state and
is incapable of entrapping contents (since there is no
aqueous interior space). Bilayer liposomes of DOPE
can be made at pHs above the pKa for the amine
group, i.e., above a pH of approximately 8.5, and
these structures will retain contents within their
aqueous interior [17]. DOPE can also be stabilized
in the bilayer state in the presence of CHEMS at pHs
where the acid is negatively charged, i.e., above a pH
of approximately 6.0 [36]. These considerations ex-
plain the results we presented in Figs. 1 and 2 for
release of HPTS from DOPE or DOPE/CHEMS
liposomes in the absence of PEG-lipid. It can also
be seen from Figs. 1 and 2 that inclusion of a small
mol% of a molecule having a bulky headgroup, e.g.,
a PEG-lipid derivative, can stabilize DOPE or
DOPE/CHEMS in the bilayer state in the pH range
of 5.5^7.4. When a disul¢de-containing lipopolymer,
mPEG-S-S-DSPE, is included in the lipid bilayer,
thiolytic cleavage of the PEG headgroup with DTT
leaves a bilayer that is inherently unstable, being
composed of only DOPE or DOPE/CHEMS and a
small amount of DSPE. As can be seen in Fig. 1B
and 2B, liposomes containing mPEG-S-S-DSPE have
an increased rate of contents release at pH 5.5,
although contents release is less rapid than that
seen for similar liposomes that never contained
PEG (Fig. 1A and 2A). A slow rate of cleavage of
mPEG-S-S-DSPE, or incomplete cleavage of mPEG-
S-S-DSPE likely contributes to the slower release
rate. Cellular enzymes extracted from cells are capa-
ble of mimicking the action of DTT in cleaving
mPEG-S-S-DSPE (Fig. 3).
DXR, but not HPTS, was rapidly released from
liposomes in 90% human plasma (Fig. 4). This might
be due to the mechanism used for DXR loading.
DXR is a weak base: the charged form of the drug
is favored at acid pH, and the neutral form of the
drug (which is membrane permeable) is favored at
basic pH. In the loading method we used for
DXR, the interior of the liposomes contains ammo-
nium sulfate. The drug in the neutral form crosses
the liposomal membrane from exterior to interior
where it is protonated, leading to the formation of
an insoluble DXR-sulfate precipitate [29]. These
preparations are very stable, with extremely slow
rates of drug release. However, DOPE will not hy-
drate to form bilayer liposomes at acid pH, so we
prepared DOPE and DOPE/CHEMS liposomes in a
pH 8.5^9.0 ammonium sulfate solution. Although
the loading e⁄ciency at this pH is greater than
95%, the neutral form of DXR is favored at pH
8.5, and hence it may not be able to form a stable
precipitate with ammonium sulfate. We have tried
forming and hydrating the pH-sensitive liposomes
at basic pH (s pH 9.0) in the presence of mPEG-
S-S-DSPE, then lowering the pH prior to drug load-
ing. Although the DOPE will stay in the bilayer state
when the pH is lowered, we have not yet been suc-
cessful in achieving pH-sensitive formulations of
DXR that do not have fairly high rates of drug re-
lease in human plasma. Future experiments may
need to be done with other antineoplastic drugs
that are more amenable to stable loading into these
DXR-containing pH-sensitive formulations.
To demonstrate the kinetics of release of DXR
from the lysosomal apparatus, the rate of accumula-
tion of DXR in cellular nuclei was measured as a
function of time by using a DXR nuclear accumula-
tion assay (Fig. 5). As expected, little nuclear uptake
of DXR was seen for DXR-SL, since it has a very
slow rate of drug release [40] and the only mecha-
nism for the drug to reach the nucleus is through
passive di¡usion into the cell of drug released from
the liposomes into the culture medium. When these
liposomes are targeted with anti-CD19 (DXR-SI-
L[anti-CD19]), nuclear levels of DXR in Namalwa
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cells increased approximately 3-fold, most likely be-
cause the liposome drug packages were taken up into
the cell by receptor-mediated internalization. How-
ever, the intracellular rate of drug release from endo-
somes is slow [15], hence the comparatively low levels
of nuclear DXR. The more rapid rates of drug re-
lease for the non-targeted pH-sensitive formulations
(at all pHs) compared with the DXR-SIL[anti-CD19]
and DXR-SL formulations led to more drug release
into the media and hence more drug delivery to the
nucleus via a passive di¡usion mechanism. It is pos-
sible, but not con¢rmed, that the DOPE and DOPE/
CHEMS formulations may also deliver some drug
into the cell cytoplasm by a fusion mechanism, and
from there it would be available to tra⁄c to the cell
nucleus. As might be predicted from their in vitro
drug release rates and their ability to trigger recep-
tor-mediated endocytosis, the targeted mPEG-S-S-
DSPE formulations have the highest rates and levels
of nuclear accumulation among the liposomal formu-
lations.
In Table 1, the cytotoxicity (IC50) values for these
formulations parallel the nuclear accumulation data,
supporting the hypothesis that not only the total
amount of uptake of liposomal drug, but also the
rate of release of the encapsulated drug governs the
cytotoxicities of liposomal drugs. Total cellular up-
take of liposomal drug can be increased via the
mechanism of receptor-mediated internalization,
and intracellular drug release can be increased
through mechanisms such as the pH-sensitive trig-
gered-release mechanism, described here. One anom-
aly is the observation that liposomes containing
mPEG-S-S-DSPE have higher nuclear accumulations
(Fig. 5), and faster rates of drug release in CFE or
bu¡er, but do not have higher cytotoxicity than
mPEG-containing liposomes (Table 1). These results
might be explained in light of the recent observations
of Goren et al. in experiments where the cytotoxicity
of folate-targeted liposomal DXR was examined in
MDR cells that overexpress the folate receptor [14].
In spite of up to 6-fold higher accumulation of DXR
in the cell nucleus, when it was delivered in targeted
liposomes relative to free drug, they were unable to
reverse multidrug resistance in their cells. The au-
thors interpret these results to mean that a long pe-
riod of time is necessary to allow for the disaggrega-
tion of DXR (dissolution of the insoluble DXR-SO4
and solubilization of DXR dimers) following the in-
ternalization of liposomes and their degradation
within the cell interior. The 48 h incubation time
that we used in our cytotoxicity experiments after
washing away the drugs may not have been long
enough to allow for su⁄cient disaggregation of the
DXR to see a di¡erence between the liposomes con-
taining mPEG-S-S-DSPE versus mPEG-DSPE.
Previous studies have shown that inclusion of
mPEG-DSPE increases the circulation half-life of
DOPE and DOPE/CHEMS formulations [24]. How-
ever, the inclusion of mPEG-S-S-DSPE did not in-
crease the circulation time of the DOPE and DOPE/
CHEMS formulations (Fig. 6). Since 10 mol% of
mPEG-DSPE in either DOPE or DOPE/CHEMS
liposomes gave signi¢cantly longer circulation half-
lives than 9 mol% mPEG-S-S-DSPE plus 1 mol%
mPEG-DSPE (Fig. 6), we believe that the short
half-life of liposomes containing mPEG-S-S-DSPE
is probably due to rapid cleavage of the disul¢de
linkage by blood components, e.g. cysteine, in vivo.
The loss of steric hindrance due to the loss of PEG
from the liposomes would decrease their stability in
blood and increase the uptake of liposomes by the
MPS.
We have previously shown that DXR-SIL[anti-
CD19] binds to, and is internalized by, human B-
lymphoma (Namalwa) cells within a few minutes
[4,15]. If this process occurs rapidly enough in vivo,
then we may still be able to achieve good therapeutic
results with targeted, mPEG-S-S-DSPE-stabilized,
pH-sensitive formulations even though these formu-
lations release the encapsulated DXR rapidly and
have short circulation half-lives in vivo. To test this
hypothesis, we conducted therapeutic studies with
these formulations in SCID mice inoculated with
CD19 Namalwa cells. In spite of their rapid leakage
and clearance, it appears that the therapeutic e⁄cacy
of anti-CD19-targeted, mPEG-DSPE-stabilized
DOPE/CHEMS liposomes was similar to that of
DXR-SIL[anti-CD19] liposomes, and the e⁄cacy of
mPEG-S-S-DSPE-stabilized DOPE/CHEMS formu-
lations was moderately higher (Table 2). The longer
time of exposure of the liposomal drugs to the cells
in vivo may have allowed more time for drug disag-
gregation, supporting the studies of Goren et al. [14].
These results strongly suggest that if retention of
encapsulated drug and stability in blood circulation
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could be further improved, then triggered release for-
mulations targeted against internalizing epitopes will
be able to substantially increase the therapeutic index
of encapsulated drug in vivo. Development of a for-
mulation that has both good drug retention proper-
ties in the presence of human plasma and prolonged
circulation time is in progress in our laboratories.
In this study, we developed targeted, pH-sensitive
liposomes sterically stabilized by PEG, which was
surface-grafted via a chemically-cleavable bond
(mPEG-S-S-DSPE). These targeted, pH-sensitive for-
mulations stabilized with mPEG-S-S-DSPE (trig-
gered-release formulations) delivered encapsulated
DXR e⁄ciently into the cytoplasm of target cells
and improved the cytotoxicity of encapsulated
DXR in vitro, relative to a targeted formulation
that lacked triggered release properties, i.e., DXR-
SIL[anti-CD19]. The targeted triggered release for-
mulations resulted in a modest increase in therapeu-
tic e⁄cacy in vivo. The usefulness of this approach
has been demonstrated in this study. Further optimi-
zation of these formulations may result in addition-
al increases in their therapeutic e⁄cacy in vivo. In
addition, the unique properties of these targeted,
triggered-release formulations may be used for the
intracytoplasmic delivery of plasmids, antisense
oligonucleotides, and ribozymes in vivo for the treat-
ment of cancer and viral infections.
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